medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2011, Número 6

<< Anterior Siguiente >>

Rev Mex Urol 2011; 71 (6)


Hipogonadismo asociado a edad avanzada

Arroyo C, Piña N, Soto E

Idioma: Español
Referencias bibliográficas: 52
Paginas: 331-337
Archivo PDF: 395.45 Kb.


RESUMEN

La deficiencia androgénica del adulto mayor o síndrome de testosterona baja, conocidos frecuentemente como andropausia, se caracteriza por signos y síntomas asociados al envejecimiento y que son parcialmente resultado de niveles inferiores de testosterona total. Se trata de un cuadro clínico que todos conocemos como parte de la pérdida de capacidades que se asocian a la edad; sin embargo, no se interrogan rutinariamente en la historia clínica del paciente.
En este artículo se busca describir el cuadro clínico, diagnóstico, tratamiento y nuevas asociaciones de la deficiencia androgénica del adulto mayor con patologías como la disfunción eréctil, obesidad y síndrome metabólico, con el objeto de revisar la bibliografía actual en este tema.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Disponible en: http://www.conapo.gob.mx/00cifras/5.htm. Consultado en noviembre 2010.

  2. Comunicación directa de la Dra. Lucina Coyotl del Sistema para el Desarrollo Integral de la Familia del estado de Puebla, D.I.F. Estatal. Disponible en: http://www.dif.puebla.gob.mx/

  3. Von Zglinicki T, Burkle A, Kirkwood T. Stress, DNA damage and ageing-an integrative approach. Exp Gerontol 2001;36:1049-62.

  4. Wick, G, Jansen-Durr P, Berger P, et al. Disease of aging. Vaccine 2000;18:1567-83.

  5. Miller N, Fulmer B. Injection, ligation and transplantation: the search for the glandular fountain of youth. J Urol 2007;177:2000-5.

  6. Pardo JM. Síndrome de deficiencia androgénica del anciano (ADAM). Rev Ven Urol 2005;51:65-74.

  7. Morales A. Lunenfeld. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM, international Society for the Study of the Aging Male. Aging Male 2002;5:74-86.

  8. Harman SM, Metter E, Tobin J, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. J Clin Endocrinol Metab 2001;86:724-31.

  9. Araujo AB, Esche G, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007;92:4241-7.

  10. Saucedo R, Fonseca M, Basurto L, et al. Decremento en los andrógenos circulantes en el hombre durante la senescencia. Gac Med Mex 2006;136:335-40.

  11. Wang C, Nieschlag E, Swerdloff R, et al. ISA, ISSAM, EUA, EAA and ASA recomendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res 2009;21:1-8.

  12. Heinemann, et al. The aging male´s symptoms (AMS) rating scale. Cultural and linguistic validations into English. The aging male 2001;41:14-22.

  13. Morales A, Heaton JPW. Hypogonadism and erectile dysfunction: pathophysiological observations and therapeutic outcomes. BJU Int 2003;92:896-9.

  14. Vermeulen A. The future of hormone replacement therapy in the aging male. Aging Male 2000;3:210-3.

  15. Rodriguez A, Muller D, Metter EJ, et al. Aging, androgens, and the metabolic sindrome in a longitudinal study of aging. J Clin Endocrinol Metab 2007;92:3568-72.

  16. Bremner WJ. Testosterone deficiency and replacement in older men. N Engl J Med 2010;363:189-91.

  17. Disponible en: www.issam.ch/freetesto.htm. Consultado en noviembre 2010.

  18. Brawer MK. Testosterone replacement in men with andropause: an overview. Rev Urol 2004;6(Suppl6):9-15.

  19. Veldhuis J, Keenan D, Li P, et al. The aging male hypothalamic-pituitary-gonadal axis: pulsatility and feedback. Mol Cell Endocrinol 2009;299:14-22.

  20. Holyoak J, Crawford E, Meacham R. Testosterone and the prostate: implications for the treatment of hypogonadal men. Curr Urol Rep 2008;9:500-5.

  21. Heikkilä R, Aho K, Heliövaara M, et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer 1999;86:312-5.

  22. Mohr BA, et al. Hormones and prostate cancer: a prospective study. Urology 2001;57:930-5.

  23. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism. JAMA 2006;296:2351-61.

  24. Schwartzer U, Sommer F, Christoph A, et al. The effect of long-term testosterone replacement therapy on prostate specific antigen and prostate volume in hypogonadal men (n = 40); results of a prospective study. J Urol 2001;165:214.

  25. Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol 2005;173:533-6.

  26. Schubert M, Minneman T, Hubler D, et al. Intramuscular testosterone undecanoate; Pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004;89:5429-34.

  27. Behre HM, Abshagen K, Oettel M, et al. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 1999 ;140:414-9.

  28. Nieschlag E, Buchter D. Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal Men. Clin Endocrinol (Oxf) 1999;51:757-63.

  29. Schubert M, Minnemann T, Hubler D. Intramuscular Testosterone undecanoate: Pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004;89:5429-34.

  30. Zhang GY, Gu YQ, Wang XH, et al. Pharmacokinetic study on inyectable testosterone undecanoate in men with hypogonadism. J Androl 1998;19:761-8.

  31. Handelsman DJ. Testosterone: use, misuse and abuse. Med J Aust 2006;185:436-9.

  32. Huebler D, Schubert M, Minneman A, et al. Effect of long term treatment with a new sustained-action testosterone undecanoate formulation for intramuscular androgen replacement therapy on sexual function and mood in hypogonadal men. International J Impotence Research 2002;14(S4):165.

  33. Morales A, Heaton J. Hypogonadism and erectile dysfunction; pathophysiological observations and therapeutic outcomes. BJU Int 2003;92:896-9.

  34. Heaton J, Morales A. Endocrine causes of impotence (non-diabetes). Urol Clin North Am 2003;30:73-81.

  35. Nieschlag E, Behere HM. Pharmacological and clinical uses of testosterone. In: Nieschlar A, Behere HM, Eds., Testosterone: action, deficiency and substitution. Berlin: Springer-Verlag; 1998.pp.294-321.

  36. Greenstein A, Mabjeesh NJ, Sofer M, et al. Does sildenafil combined with testosterone gel improve erectile dysfunction in hypogonadal men in whom testosterone supplement therapy alone failed. J Urol 2005;173:530-2.

  37. Shabsigh, R, Kaufman J, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172:658-63.

  38. Tsertsvadze A, Fink H, Yazdi F, et al. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis. Ann Intern Med 2009;151:650-61.

  39. Rosenthal B, May N, Metro M, et al. Adjunctive use of AndroGel (testosterone gel) with sildenafil to treat erectile dysfunction in men with acquired androgen deficiency syndrome after failure using sildenafil alone. Urology 2006;67:571-4.

  40. Kupelian V, Page ST, Araujo AB, et al. Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associates with development of the metabolic syndrome in non-obese men. J Clin Endocrinol Metab 2006;91:843-50.

  41. Gould DC, Kirby RS, Amoroso P. Hypoandrogen-metabolic syndrome: a potential common and underdiagnosed condition in men. Int J Clin Pract 2007;61:341-4.

  42. Gould D, Kirby R, Amoroso P. Hypoandrogen-metabolic syndrome: a potentially common and underdiagnosed condition in men. Int J Clin Pract 2007;61:341-4.

  43. Kapoor D, Malin CJ, Channer KS, Jones TH. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005;63:239-50.

  44. Muller M, Grobbee DR, den Tonkelaar I, et al. Endogenous sex hormones and metabolic syndrome in aging men. J Clin Endocrinol Metab 2005;90:2618-23.

  45. Gannage-Yared MH, Fares F, Semaan M, et al. Circulating osteoprotegerina is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population. Clin Endocrinol (Oxf) 2006;64:652-8.

  46. Chen RYT, Wittert GA, Andrews GR. Relative androgen deficiency in relation to obesity and metabolic status in older men. Diabetes Obes Metab 2006;8:429-35.

  47. Corrales J, Burgo R, Garca-Berrocal B, et al. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism 2004;53:666-72.

  48. Gould DC, Amoroso P, Kirby R. Hypoandrogen-metabolic syndrome: a significant issue for men’s health. Metabolism 2004;53:666-72.

  49. Tostain J. Menopause et andropause. Rev Prat 2007;57:537-42.

  50. Betts JM. Doping in sports: the pediatric perspective. J Urol 2007;178(4Pt2):1733-7.

  51. Heaton JPW. Hormone treatments and preventive strategies in the aging male: whom and when to treat? Rev Urol 2003;5(Suppl1):S16-21.

  52. Sharma V, Perros P. The management of hypogonadism in aging male patients. Postgrad Med 2009;121:113-21.




2020     |     www.medigraphic.com